Viruses go modular

Ariel Shepley-McTaggart, Hao Fan, Marius Sudol, and Ronald N. Harty

The WW domain is a modular protein structure that recognizes the proline-rich Pro-Pro-x-Tyr (PPxY) motif contained in specific target proteins. The compact modular nature of the WW domain makes it ideal for mediating interactions between proteins in complex networks and signaling pathways of the cell (e.g. the Hippo pathway). As a result, WW domains play key roles in both normal and disease processes. Intriguingly, RNA and DNA viruses have evolved strategies to hijack cellular WW domain-containing proteins and thereby exploit the modular functions of these host proteins for various steps of the virus life cycle, including entry, replication, and egress. In this review, we summarize key findings in this rapidly expanding field, in which new virus-host interactions continue to be identified. Further unraveling of the molecular aspects of these crucial virus-host interactions will continue to enhance our fundamental understanding of the biology and pathogenesis of these viruses. We anticipate that additional insights into these interactions will help support strategies to develop a new class of small-molecule inhibitors of viral PPxY-host WW-domain interactions that could be used as antiviral therapeutics.

The modular, compact nature of the WW domain contributes to its status as a prominent mediator of a wide array of protein-protein interactions in the cell. WW-domain ligands include short proline-rich motifs with the proline-proline-x-tyrosine (PPxY) motif serving as the consensus ligand (1–3). In mammalian cells, interactions between WW-domain and PPxY-containing proteins regulate pathways that are involved in processes such as protein ubiquitination, signaling, sorting, migration, and degradation (4–27). For example, key WW domain/PPxY interactions are critical for mediating the formation of protein complexes in the Hippo signaling pathway, which regulates cell proliferation, migration, and apoptosis (18, 24, 26, 28–30). In addition, all members of the HECT (homologues to the E6AP C terminus) family of E3 ubiquitin ligases contain multiple WW domains involved in binding to specific host PPxY-containing substrates, leading to modulation of their stability, trafficking/localization, and/or signaling functions (14, 31–37).

Intriguingly, a growing body of literature has demonstrated that modular WW domain/PPxY interactions not only are critical for regulating cellular pathways, but also play key roles in regulating one or more steps in the life cycles of many viral pathogens (38–46). Not surprisingly, select DNA and RNA viruses have evolved the ability to mimic these protein-protein interactions by using virally encoded PPxY-containing proteins to compete with cellular counterparts for binding to specific host proteins bearing one or more of these small modular WW domains, thus, in essence, hijacking cellular pathways and networks that ultimately impact both the virus and the host (see Figs. 1 and 2 and Table 1). For example, the initial discovery that viruses encode PPxY motifs to hijack host proteins to facilitate virus egress had a tremendous impact on the field because it demonstrated that viruses usurp host proteins and machinery to complete the late stage of virus-cell separation most efficiently. This discovery opened up an entirely new field of
Figure 1. Key modular PPxY/WW-domain interactions and outcomes for the retroviruses, filoviruses, and adenoviruses.

A

Retroviruses
- HIV
- RSV
- HTLV-1
- MLV

Filoviruses
- EBOV
- MARV

Adenoviruses
- AdV

Viral PPxY containing protein
- Gag
- VP40
- PVI

Host WW-domain containing protein
- HECT E3 ligases
- BAG3

Enhancement of budding
Inhibition of budding
Viral entry

B Virus-host PPxY/WW-domain interactions

1. RSV Gag
2. HTLV-1 Gag
3. EBOV VP40
4. MARV VP40
5. ADV PVI
6. EBV LMP2A
7. HHV U24

Figure 2. A, position and sequence of PPxY motifs in key viral proteins. B, representative examples of virus-host PPxY/WW-domain interaction functioning during virus exit (left; EBOV VP40) and virus entry (right; AdV PVI).
research on virus-host interactions that regulate egress. For example, the PPxY motif contained within matrix proteins encoded by RNA viruses, such as retroviruses and filoviruses, was termed a late (L) domain due to its role in facilitating the late step in virus-cell separation or pinching off (budding). In addition to the PPxY motif, PT/SAP and YxxL were also identified as functional L-domain motifs in specific RNA viruses. Intriguingly, the RNA viral L domains were found to be interchangeable and movable while retaining their function in recruiting host proteins to promote virus egress (47–50). In contrast, DNA-containing viruses, such as adenoviruses and herpesviruses, express PPxY-containing proteins that interact with specific host WW domain–bearing proteins to facilitate virus entry/internalization and affect virus replication and cancer progression, respectively.

The viruses chosen for discussion here represent the best-characterized examples of viruses that encode PPxY motifs that mediate physical and functional interactions with host WW domain–bearing proteins to influence specific stages of the virus life cycle. Part of the excitement about this discovery is that viruses that are very different from one another in terms of their genetic material, morphology, life cycle, and disease all have evolved to encode one or more PPxY motifs that interact with specific host proteins to impact their life cycles. We will discuss key findings that highlight the physical and functional nature of a wide array of virus-host PPxY/WW-domain interactions, describe how usurping of host proteins affects the biology and pathogenesis of these viruses, and finally describe recent progress to identify and develop antiviral therapeutics that target and block these modular virus-host interactions as part of a novel host-oriented strategy to combat and treat viral infections.

**Modular interactions and virus egress**

**Retroviruses**

HIV-1—Pioneering studies that first identified viral L domains and, subsequently, their ability to interact with modular WW domains of host proteins were undertaken with the Gag proteins encoded by HIV-1 and Rous sarcoma virus (RSV) (50–53). Indeed, the PPPY sequence located in the N-terminal p2b region of the Rous sarcoma virus Gag protein was the first PPxY-type L domain shown to play a key role in facilitating virion egress by interacting with cellular WW domains (51).

One of the first WW domain–bearing host proteins implicated in viral PPxY-mediated egress was Nedd4 (neuronal precursor cell–expressed developmentally down-regulated 4), the prototypic member of the HECT family of E3 ubiquitin ligases. Indeed, a plethora of reports soon followed that linked the budding pathways of several RNA viruses to Nedd4, Nedd4 family members, and/or ubiquitin (39, 41, 43–45, 54–67). Although HIV-1 Gag does not possess a PPxY motif, budding of HIV-1 was shown to be positively regulated by ubiquitin and E3 ubiquitin ligases, such as Nedd4, likely via an indirect mechanism. For example, Strack et al. (70) showed that 2–5% of the HIV-1 p60pp found in virions was monoubiquitinated and that chimeric Gag constructs with L domains from RSV and HIV-1 both produced Gag-ubiquitin conjugates in virus-like particles (VLPs). Moreover, inhibition of the proteasome, which reduces the levels of free ubiquitin in the cell, limited Gag VLP formation (69, 70). More recently, Mercenne et al. (71) demonstrated that PPxY-containing host protein angiomotin (Amot) could bind both Nedd4L and HIV Gag and serve as an adaptor protein to promote early stages of HIV-1 assembly and budding. Whereas our understanding of the precise mechanistic role of ubiquitin and E3 ubiquitin ligases in facilitating virus budding still remains unclear, one possibility is that monoubiquitination of viral matrix proteins allows them to engage one or more members of the host endosomal sorting complex required for transport (ESCRT) pathway, which subsequently mediates efficient virus-cell separation and egress of mature virions from the plasma membrane (72, 73). In contrast, other reports suggest that different mechanisms may also be involved. For example, a functional link between Nedd4 family members and HIV-1 budding was revealed by studies demonstrating that overexpression of Nedd4L could rescue budding of an HIV-1 Gag protein lacking an L-domain motif (62, 64, 74). In addition, Nedd4-mediated ubiquitination of ESCRT proteins such as Tsg101, rather than PPxY-deficient viral proteins such as HIV-1 Gag, may serve to activate ESCRT and promote budding of HIV-1 (75). Alternatively, Weiss et al. reported that Nedd4-mediated ubiquitination of HIV-1 Gag was not sufficient to stimulate virus budding, but rather the synthesis of Lys-63–

---

**Table 1**

Summary of virus-host interactions and effects on RNA and DNA viruses

| Virus family | Virus | Late domain–containing viral protein | WW domain–bearing host interactor | Effect on viral life cycle stage |
|-------------|-------|-------------------------------------|----------------------------------|--------------------------------|
| Retroviruses | HIV-1 | Gag | Nedd4, Nedd4.2/Nedd4L, Rsp5 | Enhancement of budding |
|             | RSV  | Gag | LDI-1, LDI-2, Nedd4 | Enhancement of budding |
|             | HTLV-1 | Gag | Nedd4, ITCH/AIP4, WWP1, HECW2 | Enhancement of budding |
| Filoviruses  | EBOV | VP40 | Nedd4, WW4P1, WW2P2, ITCH/AIP4, ART proteins | Enhancement of budding |
|             | MARV | VP40 | Nedd4, Rsp5, ITCH, WW1 | Inhibition of budding |
| Herpesviruses | EBV | LMP2A | Nedd4, Nedd4.2/Nedd4L, WWP2, ITCH/AIP4 | Viral latency |
|             | EBV | LMP2A | Nedd4, WW4P1, WW2P2, ITCH/AIP4 | Viral latency |
|             | HHV | U24 | Nedd4.1, Nedd4.2/Nedd4L, SMURF-2 | Neurologic disease progression |
| (Roseolovirus) |                 |             |                   |                           |
| Adenoviruses | Adv  | PVI | WWP1, WWP2, AIP4/ITCH, Nedd4.1, Nedd4.2/Nedd4L | Viral entry |
| Tombusviruses | TBSV | p92pol, p33<sup>a</sup> | Rsp5 | Immune modulation |
| Orthomyxoviruses | Influenza | IFITM3 (cellular) | Nedd4 | Immune modulation |

<sup>a</sup> All proteins listed are viral proteins except for IFITM3.

<sup>b</sup> p92pol and p33 do not contain canonical late domain motifs.
linked ubiquitin chains in the vicinity of the viral bud was critical for E3 ligase-mediated virus budding (65). Indeed, the authors postulate that the Lys-63–linked ubiquitin chains on viral or cellular substrates are sensed or recognized by components of the ESCRT machinery, which is subsequently recruited to facilitate virus egress (65).

**RSV**—Unlike HIV-1, retroviruses whose Gag proteins do contain PPxY motifs can physically and functionally interact directly with the modular WW domains of either Nedd4 or Nedd4 family members to facilitate their egress and spread. For example, early work by Kikonyogo and colleagues (56), in which they screened a chicken embryo cDNA expression library with a peptide containing the PPxY L-domain sequence from RSV Gag-p2b, identified two WW-domain interactors they named late domain–interacting proteins 1 and 2 (LDI-1 and -2). LDI-1 was found to share sequence homology with Xenopus Nedd4, whereas LDI-2 exhibited homology to other members of the Nedd4 family, specifically human WWP1 and the murine E3 ubiquitin ligase, ITCH (also known as AIP4) (56). The authors also demonstrated that budding of RSV Gag required the PPxY L domain and that overexpression of the isolated WW domains of LDI-1 acted in a dominant-negative manner to inhibit budding (56, 76). In a follow-up study, Vana et al. (45) demonstrated that a catalytically active LDI-1 protein was required to promote RSV Gag egress, as a catalytically inactive LDI-1 mutant blocked Gag release. Whereas they were able to detect both mono- and polyubiquitinated forms of Gag within cells, the monoubiquitinated form of Gag was most prevalent in budded VLPs, and ubiquitination of RSV Gag depended on its PPxY L domain.

**Human T-cell leukemia virus 1 (HTLV-1)**—The PPPYVE-PTAP sequence at the C terminus of the HTLV-1 Gag protein contains a PPxY and PTAP L-domain motif, both of which were shown to play a role in facilitating release of HTLV-1 Gag VLPs; however, the PPxY motif appeared to be more important for efficient egress (39, 43, 59). HTLV-1 Gag was shown to interact with WW domains of E3 ligases Nedd4, BUL1, and HECW2 (HECT, C2, and WW domain–containing E3 ubiquitin ligase 2) (39, 43, 59), and results from Blot et al. (59) suggested that the HTLV-1 PPxY motif first recruited host Nedd4, which then allowed the virus to engage the ESCRT complex, specifically Tsg101, to promote efficient assembly and egress of virus particles. Indeed, Tsg101 is a key component of the ESCRT-1 complex that can interact with viral PTAP L-domain motifs and can also bind to ubiquitinated proteins, thus mediating their engagement of the ESCRT machinery. Later studies both confirmed and expanded the repertoire of host WW domain–bearing E3 ligases hijacked by the PPxY motif of HTLV-1 Gag to benefit egress and spread of virus particles. For example, HECT family E3 ubiquitin ligase WWP1, which possesses four WW domains, was shown to ubiquitinate a lysine residue at position 74 of HTLV Gag to promote efficient virus egress (77, 78). In contrast, a lysine 74 mutant of HTLV-1 Gag was not ubiquitinated and was budding-defective. Dorjbal et al. (66) went on to test nine members of the Nedd4 family of E3 ubiquitin ligases (Nedd4, Ned4L, BUL1, BUL2, WWP1, WWP2, ITCH, SMURF1, and SMURF2) for their ability to promote egress of HTLV-1 and found that ITCH was the main contributor to HTLV-1 budding. Also of interest was their finding that the physical binding efficiencies between the viral PPxY motif and the various host WW domains did not correlate with their functional effect on HTLV-1 budding (66).

**Murine leukemia virus (MLV)**—Studies by Martin-Serrano and colleagues (79) helped to solidify the functional link between HECT E3 ubiquitin ligases recruited by viral PPxY motifs and the ESCRT pathway during egress of WT or chimeric MLV Gag proteins. Using an array of WW domain–containing E3 ligases and chimeric MLV Gag proteins containing the PPxY motifs and flanking residues from either host amiloride-sensitive sodium channel (ENaC), RSV Gag-p2b, or Ebola virus VP40 proteins, they demonstrated that the E3 ligase WWP1 was recruited to sites of MLV budding in a PPxY-dependent manner and that enhancement of budding required a catalytically active HECT domain (79). They concluded that the HECT ubiquitin ligases likely served as cofactors for viral PPxY-mediated budding and provided a critical link to the ESCRT complex that mediated the final step of virus-cell separation. In a later study by the same group, they demonstrated that host PPxY containing arrestin-related trafficking (ART) proteins could function as adaptors, linking WW domain–containing HECT ubiquitin ligases to the ESCRT machinery (80). Indeed, they showed that the ART proteins could be recruited to sites of PPxY-dependent viral budding and likely served as a platform for ubiquitination during the budding process (80). Thus, it is interesting to speculate that the PPxY-containing viral matrix proteins have evolved to mimic and/or compete with cellular ART-like proteins for binding to modular WW domains to regulate virus egress and spread.

**Filoviruses: Ebola (EBOV) and Marburg (MARV) viruses**

Filoviruses (EBOV and MARV) are emerging pathogens that can cause severe hemorrhagic disease with high mortality rates in primates and humans (81–83). There has been growing interest in elucidating the molecular mechanisms used by these viruses to bud and spread from cells, as well as in identifying novel virus–host interactions that contribute to the transmission and pathogenesis of these deadly viruses. The filovirus matrix protein, VP40, is the major structural component of filoviruses and plays a key role in directing virion assembly and promoting virion egress during late stages of filovirus replication (54, 84–88). Intriguingly, a number of groups have shown that independent expression of filovirus VP40 leads to the production and egress of filamentous VLPs that mimic the morphology of authentic filoviruses (44, 54, 89–94). Thus, VP40 has been the focus of numerous studies to examine the molecular mechanisms and host interactors that regulate filovirus egress. As described above for the Gag proteins of many retroviruses, L domains are highly conserved in the VP40 matrix proteins of all known EBOV and MARV species. Indeed, both EBOV and MARV VP40 proteins contain a PPxY-type L-domain motif that can compete with cellular counterparts for binding to specific WW domain–bearing host proteins, thus hijacking critical cellular pathways that impact both the virus and the host. It should be mentioned that EBOV VP40 and MARV NP (nucleoprotein) proteins contain a PT/SAP-type L domain as well,
and PT/SAP has been proposed to interact with and recruit host Tsg101 to facilitate virion egress (91, 95–98). Recent findings describing key modular interactions between filoviral PpxY motifs and host WW-domain interactors will be discussed below.

Harty et al. (54) were the first to demonstrate a role for the PpxY motif of EBOV VP40 in budding of VLPs and in interacting physically and functionally with host WW domains of E3 ligase Nedd4 and its yeast ortholog Rsp5. A series of reports soon followed that demonstrated that the VP40 PpxY motifs of both EBOV and MARV functioned in a manner similar to that described earlier for both retroviral and rhabdoviral (55, 89, 99–101) PpxY motifs to recruit host interactors and ESCRT to facilitate egress (Fig. 2A) (44, 54, 58, 60, 91, 96, 97, 102). Most of the early work on the filovirus VP40 PpxY motif was centered on its role in hijacking Nedd4 and ultimately the ESCRT complex to facilitate budding. More recent developments were based on utilization of a strategy involving screening of a specially prepared array composed of a complete set of bacterially expressed and purified human WW domains with either WT or PpxY-mutant peptides from EBOV or MARV VP40 to identify novel WW-domain interactors that may regulate filovirus budding (41, 42, 103). Interestingly, the authors found that there was an unprecedented degree of specificity, in that the filoviral WT PpxY motifs bound to only a select number of host WW domains (41, 42, 103). In addition to the expected WW-domain interactors like Nedd4 and Rsp5, the newly identified VP40 hits from this screen included HECT family E3 ubiquitin ligases ITCH (AIP4) and WW1P (41, 42) previously identified as Gag interactors. In addition, BCL2-associated athanogene 3 (BAG3); a WW domain–bearing member of the BAG family of molecular co-chaperone proteins involved in regulating protein homeostasis and cell survival through chaperone-assisted selective autophagy (CASA), was identified as a novel VP40 interactor (103).

Han et al. (41) confirmed that EBOV VP40 interacted with ITCH in a PpxY/WW domain–dependent manner, as determined by co-immunoprecipitation of full-length proteins, and that the enzymatically active form of ITCH was required to monoubiquitinate EBOV VP40, leading to enhanced egress of VP40 VLPs. In addition, the authors used both siRNA knockdown/rescue assays and ITCH knockout cells to demonstrate further the biological importance of ITCH for VP40 budding in this VLP system and for egress of recombinant VSV engineered to express the PpxY L domain of EBOV VP40 (41, 97). These data demonstrated that EBOV VP40 likely recruits host E3 ligase ITCH via the PpxY/WW-domain modular interaction to promote efficient egress of EBOV VLPs and VSV-EBOV recombinant viruses and, although yet to be proven, imply that a similar modular recruitment of ITCH may occur during authentic EBOV infection.

Similar findings were reported by Han et al. (42) for E3 ligase WWP1 and EBOV VP40, again demonstrating that the interaction between WWP1 and VP40 is PpxY/WW domain–dependent and that monoubiquitination of VP40 by enzymatically active WWP1 led to enhanced egress of VP40 VLPs (42). Not surprisingly, both ITCH and WWP1 interact with a plethora of cellular proteins to regulate multiple pathways and networks in mammalian cells (37). For example, ITCH plays a key role in regulating lymphocyte activation and differentiation, key processes in immune regulation and inflammatory signaling (104). Likewise, WWP1 functions in protein signaling and trafficking related to transforming growth factor β and epidermal growth factor signaling, as well as apoptosis and neurological diseases (37). Whereas recruitment or hijacking of E3 ligases, such as Nedd4, ITCH, and WWP1, may facilitate egress and modulate the pathogenesis of infectious EBOV, the potential effects of these modular interactions on normal host protein function remains unclear. In addition, whether the ability of filovirus VP40 and other PpxY-containing viral proteins to interact with a wide array of WW-domain interactors is linked to the expression levels of these ligases in various cell types and reflects the cellular tropism of the virus, or is simply a mechanism of built-in redundancy used by the virus, remains to be determined.

Using the previously mentioned human WW-domain array, Liang et al. (103) identified host BAG3 as a novel WW-domain interactor with the PpxY motifs of both EBOV and MARV VP40. BAG3 is a stress-induced protein that regulates cellular protein homeostasis and cell survival through the CASA pathway (11, 105). The authors confirmed the PpxY/WW-domain–dependent interaction between BAG3 and both EBOV and MARV VP40 and, intriguingly, demonstrated that expression of BAG3 negatively regulated budding of both EBOV and MARV VP40 VLPs as well as egress of infectious VSV-EBOV recombinants (103). This finding was novel because all previously identified host WW-domain interactors with VP40 positively regulated VLP and/or virus egress (103). The authors speculated that BAG3 and CASA may function as a host defense mechanism, whereby BAG3 recognizes and interacts with the viral PpxY motifs, thereby dampening virus egress by interfering with the budding function of viral PpxY-containing matrix proteins. Recently, BAG3 and the CASA machinery were reported to regulate both the synthesis and degradation of filamin, a key actin-cross-linking protein at the plasma membrane that modulates cell adhesion and migration (106–110). BAG3 is also involved in regulating the disassembly of the actin-based contractile ring during cytokinesis (cell-cell separation) (111, 112). Cytokinesis is topologically equivalent to a virion budding from the cell surface (virus-cell separation), and both processes involve some of the same host pathways (113–121). One possibility is that BAG3 and the CASA machinery regulate actin-based dynamics, stress, and membrane tension necessary for efficient pinching off of VLPs and/or viruses (122, 123). Liang et al. (103) used confocal microscopy to show that VP40 appeared to be sequestered away from the plasma membrane and accumulated in cytoplasmic aggregates in cells expressing WT BAG3, which correlated with a decreased efficiency of VLP egress. Although more studies are needed, it will also be of interest to investigate the potential interplay and binding competition between WW-domain–bearing host proteins that positively regulate virus egress (e.g. ITCH) versus those that negatively regulate virus egress (e.g. BAG3) as a means to better understand the biological impact of these dueling modular interactions.
Modular interactions and virus entry/replication

Adenoviruses

Although most PPxY motifs encoded by RNA viruses hijack HECT-family, WW-domain interactors to promote virion egress, the adenovirus PPxY/host interaction was unique in that it was one of the first discoveries of a viral PPxY motif functioning in virus entry rather than virus egress. Indeed, both the adenoviral membrane lytic internal capsid protein VI (PVI) and the capsid penton base protein possess PPxY motifs that play a role in adenovirus (AdV) entry. AdV is a nonenveloped dsDNA virus, which enters cells by receptor-mediated endocytosis and utilizes the penton base protein for internalization, as well as escape from endosomes. In 2002, Galinier et al. (40) screened a human lung expression library for host proteins that may influence adenoviral entry by interacting with the two PPxY motifs in the N-terminal region of the penton base polypeptide chain. They found that the first PPxY motif was critical for mediating interactions with WW-domain E3 ligases WWP1, WWP2 (also known as AIP2), and ITCH (40), providing the first demonstration that a nonenveloped DNA virus employed a PPxY motif to interact with host HECT-family ligases.

AdV requires exposure of the internal PVI capsid protein to breach the endosomal membrane and escape into the cytosol to complete the internalization step. Wodrich et al. (124) identified a functional PPxY motif within PVI that recruited both Nedd4.1 and Nedd4.2, leading to ubiquitination of PVI. They went on to show that the PPxY motif within PVI was required for microtubule-dependent intracellular trafficking to the nucleus and that PPxY mutants were able to escape the endosome, but were defective in trafficking to the nucleus (Fig. 2B) (124). Later findings by the same group suggested that recruitment of Nedd4 by the PPxY motif of PVI was a strategy used by the virus to divert the host E3 ubiquitin ligase from its physiological function in regulating autophagy, thus allowing the virus to evade the host autophagic response (125, 126). Indeed, the authors observed that the WT PPxY motif of PVI prevented efficient formation of autolysosomes, and they speculated that the WT virus may interfere with elongation of the autophagosomal membrane, thereby preventing autophagosome formation (125, 126). In sum, these novel findings were the first to demonstrate that the modular interaction between the adenoviral PPxY motif and the WW domain(s) of Nedd4 not only promoted efficient viral entry and trafficking, but also represented a unique strategy for the virus to reduce antigenic presentation and evade the host immune response (125, 126).

Herpesviruses

Epstein–Barr virus (EBV; human gammaherpesvirus 4)—Epstein–Barr virus is a human herpesvirus that infects lymphoid and epithelial cells to cause infectious mononucleosis. EBV establishes a lifelong latent state in the absence of replicative gene expression in B-cells, and the viral latent membrane proteins (LMP1, -2A, and -2B) are expressed in latency to antagonize the normal process of B-lymphocyte activation. Indeed, LMP2A plays a key role in enhancing the development of tumors and the transformation potential of cells. LMP2A, which helps maintain EBV latency, contains two highly conserved PPPPY motifs that were first identified by Longnecker and colleagues (127–129) and were shown to interact with WW domains. Two groups went on to show that the PPxY motifs of LMP2A recruited host proteins ITCH (AIP4), WWP2, Nedd4L, and/or Nedd4 via one or more of their modular WW domains (46, 127). Indeed, Winberg et al. (46) found that these E3 ubiquitin ligases formed PPxY/WW domain–dependent complexes with LMP2A in EBV-infected B-cells, which they suggested may lead to ubiquitination of Lyn and Syk tyrosine kinases to ultimately block B-cell signaling. In support, Ikeda et al. (127) demonstrated a reduction in the normal cellular levels of Lyn and LMP2A, suggesting that recruitment of Nedd4-like ubiquitin ligases via the viral PPxY motifs resulted in ubiquitin-mediated degradation of Lyn and LMP2A, thus modulating B-cell signal transduction.

More recently, Lan et al. (130) described an intriguing interaction between the PPxY motifs of EBV LMP2A and a host WW domain—containing oxidoreductase (WOX1) that functions, in part, as a tumor suppressor. They report that WOX1 is important for cancer-promoting effects triggered by LMP2A and, specifically, that the PPxY/WW-domain interactions between LMP2A and WOX1 were important for induction of matrix metalloproteinase 9 (MMP9). These findings suggest that the modular interactions between the PPxY motifs of EBV LMP2A and the WW domain on host WOX1 may be crucial for invasiveness and cancer progression associated with EBV infection (130).

Roseoloviruses (human betaherpesviruses: HHV-6A, HHV-6B, and HHV-7)—Roseoloviruses, also known as human herpesvirus types 6A, 6B, and 7 (HHV-6A, HHV-6B, and HHV-7), have been linked to several neurological diseases, including encephalitis, epilepsy, and multiple sclerosis (MS). The roseoloviral protein U24 is a C-tail–anchored membrane protein shown to affect recycling and endocytosis of cell-surface receptors (131, 132). In addition, U24 function may be linked to MS, as it has been found to mimic the interaction of myelin basic protein’s function with its binding partner Fyn (133, 134). The N-terminal region of U24 encoded by HHV-6A and HHV-7 contains a PPxY motif that was shown to interact with HECT-family E3 ligases SMURF2 and Nedd4, albeit more strongly with WW domain 3 of Nedd4 (135). Importantly, because sodium channels have been found to be associated with MS lesions, investigators speculated that U24 may interfere with the endosomal recycling of sodium channels known to be regulated by Nedd4. Although still speculative, results from Sang et al. (133) suggest that the PPxY motif of U24 and its strong interaction with WW domain 3 of Nedd4 may play a role in MS or other related demyelinating diseases.

Tombusviruses: Tomato bushy stunt virus (TBSV)

Tomato bushy stunt virus is an RNA virus with a small positive-stranded RNA genome that infects plants, and the virus encodes a handful of viral proteins that are unable to support viral replication without contributions from host factors. Plants have developed innate and adaptive immune pathways, including cell-intrinsic restriction factors (CIRFs), that limit plant virus replication and disease (136). Indeed, the yeast E3 ubiqui-
Modular interactions and innate immunity

**Orthomyxoviruses**

Influenza A and B viruses—Influenza viruses do not encode any functional PPxY motifs; however, a recent report described the indirect effect of a host PPxY/WW domain modular interaction on the innate immune response and susceptibility to influenza virus infection (139). Interferon-induced transmembrane protein 3 (IFITM3) is a PPxY-containing innate immune protein that restricts influenza virus infection, and levels of IFITM3 are regulated by ubiquitination following binding of IFITM3 to the WW domains of E3 ligase Nedd4 (139). Chesarino et al. (139) demonstrated that endogenous Nedd4 and IFITM3 colocalized with lysosomal markers in cells and that Nedd4–dependent regulation of IFITM3 levels affected the susceptibility of both cells and mice to infection with influenza A and B viruses. For example, knockdown of endogenous Nedd4 resulted in an increase in both IFITM3 levels and in cellular resistance to influenza virus infection, and the PPxY motif of IFITM3 was required for Nedd4-mediated ubiquitination (139). Overall, these findings suggest that short-term pharmacological inhibition of Nedd4’s modular interaction with IFITM3 could represent a novel therapeutic strategy to prevent infection by influenza viruses and perhaps other IFITM3-sensitive viruses as well.

**Filoviruses and other PPxY-containing viruses**

The viral PPxY/host WW-domain interface represents an attractive target for the development of small-molecule or peptide-based inhibitors that are often referred to as “host-oriented” therapeutics because they are designed to target a virus-host interface rather than a viral protein. For some of the viruses discussed above, these therapeutics would be predicted to inhibit efficient virus egress and spread by preventing the viral matrix protein from recruiting WW-domain partners and subsequent egress machinery (Fig. 3). Potential advantages of this host-oriented strategy include the widespread conservation of the viral PPxY as well as other L-domain motifs in a wide array of viral matrix proteins, such that an effective therapeutic may have broad-spectrum activity against numerous viral pathogens. In addition, host-oriented inhibitors may diminish the emergence of drug-resistant viral mutations, particularly for RNA viruses, and may lead to a paradigm shift in the search for better antiviral drugs. Because these PPxY/WW-domain interactions represent a common mechanism for mediating...

---

**Figure 3. Schematic diagram of filovirus budding in the absence (left) or presence (right) of host-oriented PPxY/WW-domain interaction inhibitors.**

---

The viral PPxY/host WW-domain interface represents an attractive target for the development of small-molecule or peptide-based inhibitors that are often referred to as “host-oriented” therapeutics because they are designed to target a virus-host interface rather than a viral protein. For some of the viruses discussed above, these therapeutics would be predicted to inhibit efficient virus egress and spread by preventing the viral matrix protein from recruiting WW-domain partners and subsequent egress machinery (Fig. 3). Potential advantages of this host-oriented strategy include the widespread conservation of the viral PPxY as well as other L-domain motifs in a wide array of viral matrix proteins, such that an effective therapeutic may have broad-spectrum activity against numerous viral pathogens. In addition, host-oriented inhibitors may diminish the emergence of drug-resistant viral mutations, particularly for RNA viruses, and may lead to a paradigm shift in the search for better antiviral drugs. Because these PPxY/WW-domain interactions represent a common mechanism for mediating...
egress for a wide range of RNA viruses, a combination of inhibitors targeting early stages of the virus life cycle along with those targeting this late step in budding may represent a highly effective therapeutic mixture. Considering the small size of functionally folded WW domains (less than 38 amino acids) and the rigid structure of PPxY L domains, which form polyproline type II helices, engineering of their respective polypeptides and peptides into expression vectors may serve as competitors of L domain/E3 ligase interactions. Indeed, a successful interference with Rous sarcoma virus budding from cells by cis overexpression of a WW domain supports this avenue of potential interventions to harness retro- and filoviremias in vivo (76).

Several recent studies support the feasibility of small-molecule inhibition of PPxY/WW-domain interactions as an antiviral strategy for PPxY-containing RNA viruses. First, an in silico strategy was employed by Han et al. (148) to identify existing small-molecule compounds from a ZINC database that could potentially block the interaction between the PPxY L-domain motif of EBOV and the modular WW domain of host protein Nedd4 (149, 150). Functional activity of the best candidate inhibitors was assessed by using filovirus VLP budding assays, as well as infectious virus budding assays employing VSV-WT, VSV recombinants expressing EBOV L-domain motifs, and rabies virus, all of which contain PPxY motifs. The authors showed that the most potent compounds (e.g. compound 5) had broad-spectrum anti-budding activity against PPxY-containing matrix proteins from filoviruses, rhabdoviruses, and arenaviruses with little to no cytotoxicity at the inhibitory concentrations used (148). Importantly, the candidate inhibitors significantly reduced the budding of live infectious VSV and rabies virus in cell culture compared with that observed in the presence of structurally related negative controls.

To gain a better understanding of how the viral PPxY motif fits into the WW-domain pocket of Nedd4 and how inhibitors like compound 5 may antagonize this virus-host interaction, modeling and docking analyses were performed using the NMR structure of human Nedd4-WW3 domain and the Ebola VP40-derived PPxY peptide (Protein Data Bank entry 2KQ0), with and without compound 5 (Fig. 4). The peptide-binding site in the WW3 domain contains two subpockets. This study revealed that the second proline residue from the PPxY motif in the EBOV VP40 peptide occupies the first subpocket, surrounded by WW3 residues Asn-24, Phe-28, Thr-37, and Trp-39 (Fig. 4A), and that the tyrosine residue from the EBOV VP40 PPxY motif occupies the second subpocket, surrounded by Arg-20, Ile-30, His-32, and Lys-35 (Fig. 4A). Besides hydrophobic interactions, the peptide also forms one hydrogen bond and one salt bridge with WW3 residues Asn-24 and Arg-20, respectively (Fig. 4A). The docked conformation of compound 5 showed reasonable shape complementarity to this binding site, with its quinoxaline bicyclic moiety forming the first subpocket, its phenyl ring occupying the second pocket, and its urea moiety forming hydrogen-bonding interactions with Arg-20 in the WW3 domain (Fig. 4B). Thus, compound 5 could directly compete with the EBOV VP40 peptide in binding to the human Nedd4-WW3 domain (Fig. 4C), which would correlate with its anti-budding activity observed by Han et al. (148). Whereas the authors reported little to no cytotoxicity of compound 5 in these in vitro assays, additional experiments will be essential to assess any effects of the inhibitor on the normal cellular functions of Nedd4 and/or other related E3 ligases.

In a follow-up report by Loughran et al. (151), the authors described the preparation of a series of quinoxaline-2-mercapto-acetyl-urea analogs of compound 5, which were evaluated for their ability to inhibit filoviral VLP and virus egress using assays described above. The new analogs inhibited both VP40 VLP and live recombinant VSV virus budding in the low nanomolar range, with little to no cytotoxicity, good human microsomal stability, and no inhibition of P450 3A4 at 33 μM concentration (151). The efficacy of lead candidate inhibitors to block egress of authentic hemorrhagic fever viruses in vitro and in vivo remains to be determined. Identification of inhibitors that block such interactions may be useful for a wide array of PPxY-containing viruses that hijack or recruit WW domain-containing E3 ligases during the late step of budding. Such inhibitors may be particularly useful for the treatment of Ebola virus disease, as EBOV was shown recently to cross the blood-brain barrier and re-emerge months later in the central nervous system and eye, as well as in other immunologically privileged sites that are inaccessible to antibody therapy (152–165).

Whereas progress to date on the identification and development of host-oriented, small-molecule therapeutics that target virus-host interactions is still in the early stages, these studies indicate that this new therapeutic strategy is feasible in vitro and worth pursuing in vivo. However, a number of challenges and hurdles remain, one of which includes the potential for these therapeutics to disrupt key cellular protein WW-domain interactions, leading to possible side effects from these com-
pounds. Indeed, the precise target(s) of these compounds remains to be determined, as does their possible effects on normal host protein functions. Nevertheless, the demonstration that WW domains are potentially druggable (30) and the high specificity of viral L domain interactions with their cognate protein domains support further investigations into this approach to control egress of RNA viruses like EBOV. In support of strategic shifts in drug discovery efforts, recent successes have been achieved with the use of stapled peptides (166–168) and cell-penetrating cyclic peptides (68), which are designed to target specific intracellular protein–protein interactions. Indeed, Zhang et al. (168) demonstrated that stapled peptides targeting dimer formation of the HIV-1 capsid protein showed potent antiviral activity against a broad array of viral isolates, including strains that were resistant to reverse transcriptase and protease inhibitors. In sum, the continued pursuit of fundamental and new insights into the virus–host interface will ultimately lead to the development of novel antiviral targets and strategies.

Conclusions and outlook

Whereas studies described above highlight the key roles that host WW-domain interactors play in regulating various stages of RNA and DNA virus life cycles, a number of questions remain. For example, are there additional cis- and/or trans-acting factors that influence or regulate the selective binding of the viral PpXY motif to a particular host WW domain during a virus infection? Do host PpXY-bearing proteins that interact with cellular WW domains compete with viral PpXY motif–containing proteins in infected cells? With more than 1,200 PpXY motifs represented in over 1,000 human proteins, and with the number of predicted, functional human WW domains being more than 90, the potential repertoire of WW-domain–PpXY complexes in cells seems vast. Therefore, it will be important to understand the spatial, temporal, topological, and structural levels of specificity that make signaling by PpXY L domains and host proteins so discrete and biologically critical for the life cycles of many different viruses. As such, studies of highly conserved PpXY motifs and their shared interactions with modular WW domains of host interactors will likely provide new and valuable insights into the mechanisms of viral budding and transmission, entry, immune evasion, and genome replication for a wide array of viral pathogens.

If indeed antivirals targeting PpXY/WW-domain interactions are to be pursued and developed, it will be critical to assess the potential cytotoxic effects of such antiviral compounds and determine the specificity for these compounds to interfere with virus–host PpXY/WW-domain interactions, rather than with host–host PpXY/WW-domain interactions. Although the treatment regimen for such an inhibitor would likely be brief when used to target acute viral infections, the potential side effects on normal host protein function would still need to be assessed. In addition, the wide array of host WW domains and their potential to be affected by these host-oriented therapeutics must be taken into consideration when developing these compounds. To date, there does appear to be specificity in PpXY binding to select WW domains, and a better understanding of the nature of this specificity will be crucial to ensure that any antiviral inhibitor will exhibit the same specificity for its target.

Acknowledgments—We thank members of the Harty, Fan, and Sudol laboratories for helpful comments and suggestions, Leslie King for critical reading of the manuscript, and Deborah Argento for help in preparing figures. We apologize for any references that were inadvertently omitted from this article.

References

1. Chen, H. I., and Sudol, M. (1995) The WW domain of Yes–associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc. Natl. Acad. Sci. U.S.A. 92, 7819–7823 CrossRef Medline
2. Kay, B. K., Williamson, M. P., and Sudol, M. (2000) The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 14, 231–241 CrossRef Medline
3. Sudol, M., Cesareni, G., Superti-Furga, G., and Just, W. (2012) Special issue: modular protein domains. FEBS Lett. 586, 2571 CrossRef Medline
4. Hu, H., Columbus, J., Zhang, Y., Wu, D., Lian, L., Yang, S., Goodwin, J., Luczak, C., Carter, M., Chen, L., James, M., Davis, R., Sudol, M., Rodwell, J., and Herrero, J. J. (2004) A map of WW domain family interactions. Proteomics 4, 643–655 CrossRef Medline
5. Sudol, M., and Hunter, T. (2006) NeW wrinkles for an old domain. Cell 103, 1001–1004 CrossRef Medline
6. Einbond, A., and Sudol, M. (1996) Towards prediction of cognate complexes between the WW domain and proline-rich ligands. FEBS Lett. 384, 1–8 CrossRef Medline
7. Isley, J. L., Sudol, M., and Winder, S. J. (2002) The WW domain: linking cell signalling to the membrane cytoskeleton. Cell. Signal. 14, 183–189 CrossRef Medline
8. Jamous, A., and Salah, Z. (2018) WW-domain containing protein roles in breast tumorigenesis. Front. Oncol. 8, 580 CrossRef Medline
9. McLaughlin, D. M., and Miller, C. C. (2008) The FE65 proteins and Alzheimer’s disease. J. Neurosci. Res. 86, 744–754 CrossRef Medline
10. Reuven, N., Shanzner, M., and Shaul, Y. (2015) Tyrosine phosphorylation of WW proteins. Exp. Biol. Med. (Maywood) 240, 375–382 CrossRef Medline
11. Rosati, A., Graziano, V., De Laurenzi, V., Pascale, M., and Turco, M. C. (2011) BAG3: a multifaceted protein that regulates major cell pathways. Cell Death Dis. 2, e141 CrossRef Medline
12. Rotin, D. (2008) Role of the UPS in Liddle syndrome. BMC Biochem. 9, S5 CrossRef Medline
13. Salah, Z., Alan, A., and Aqeilain, R. I. (2012) WW domain-containing proteins: retrospectives and the future. Front. Biosci. (Landmark Ed.) 17, 331–348 CrossRef Medline
14. Staub, O., Abriel, H., Plant, P., Ishikawa, T., Kanelis, V., Saleki, R., Horisberger, J. D., Schild, L., and Rotin, D. (2000) Regulation of the epithelial Na⁺ channel by Nedd4 and ubiquitination. Kidney Int. 57, 809–815 CrossRef Medline
15. Staub, O., and Rotin, D. (1996) WW domains. Structure 4, 495–499 CrossRef Medline
16. Sudol, M. (1996) Structure and function of the WW domain. Prog. Biophys. Mol. Biol. 65, 113–132 CrossRef Medline
17. Sudol, M., Chen, H. I., Bougeret, C., Einbond, A., and Bork, P. (1995) Characterization of a novel protein–binding module—the WW domain. FEBS Lett. 369, 67–71 CrossRef Medline
18. Sudol, M., and Harvey, K. F. (2010) Modularity in the Hippo signaling pathway. Trends Biochem. Sci. 35, 627–633 CrossRef Medline
19. Sudol, M., Recinos, C. C., Abracinskas, J., Humbert, J., and Farooq, A. (2005) WW or WoW: the WW domains in a union of bliss. IUBMB Life 57, 773–778 CrossRef Medline
20. Sudol, M., Siwa, K., and Russo, T. (2001) Functions of WW domains in the nucleus. FEBS Lett. 490, 190–195 CrossRef Medline
21. Zarrinpar, A., Bhattacharyya, R. P., and Lim, W. A. (2003) The structure and function of proline recognition domains. Sci. STKE 2003, RE8 CrossRef Medline
22. Chang, N. S. (2002) A potential role of p53 and WOXI in mitochondrial apoptosis (review). Int. J. Mol. Med. 9, 19–24 Medline
23. Chen, S. J., Huang, S. S., and Chang, N. S. (2013) Role of WWOX and NF-κB in lung cancer progression. Transl. Respir. Med. 1, 15 CrossRef Medline
24. Chen, Y. A., Lu, C. Y., Cheng, T. Y., Pan, S. H., Chen, H. F., and Chang, N. S. (2019) WW domain-containing proteins YAP and TAZ in the Hippo pathway as key regulators in stemness maintenance, tissue homeostasis, and tumorigenesis. Front. Oncol. 9, 60 CrossRef Medline
25. Aqeilan, R. I. and Aqeilan, R. I. (2011) WW domain interactions regulate the Hippo tumor suppressor pathway. Cell Death Dis. 2, e172 CrossRef Medline
26. Salah, Z., and Aqeilan, R. I. (2011) WW domain interactions regulate the Hippo tumor suppressor pathway. Cell Death Dis. 2, e172 CrossRef Medline
27. Tanna, M., and Aqeilan, R. I. (2018) Modeling WWOX loss of function in vivo: what have we learned? Front. Oncol. 8, 420 CrossRef Medline
28. Hergovich, A. (2012) Mammalian Hippo signalling: a kinase network regulated by protein-protein interactions. Biochem. Soc. Trans. 40, 124–128 CrossRef Medline
29. Muller, R. U., and Schermer, B. (2019) Hippo signalling—a central player in cystic kidney disease? Pediatr. Nepliro. CrossRef Medline
30. Sudol, M., Shields, D. C., and Farrow, A. (2012) Structures of YAP protein domains reveal promising targets for development of new cancer drugs. Semin. Cell Dev. Biol. 23, 827–833 CrossRef Medline
31. Aki, D., Zhang, W., and Liu, Y. C. (2015) The E3 ligase Itch in immune regulation and beyond. Immunol. Rev. 266, 6–26 CrossRef Medline
32. Flores, S. Y., Debonneville, C., and Staub, O. (2003) The role of Ned44/Nedd4-like ubiquitin ligases in epithelial transport processes. Pflugers Arch. 446, 334–338 CrossRef Medline
33. Ingham, R. J., Gish, G., and Pawson, T. (2004) The Nedd4 family of E3 ubiquitin ligases: functional diversity within a common modular architecture. Oncogene 23, 1972–1984 CrossRef Medline
34. Koganti, P., Levy-Cohen, G., and Blank, M. (2018) Smurfs in protein homeostasis, signaling, and cancer. Front. Oncol. 8, 295 CrossRef Medline
35. Rotin, D., Staub, O., and Hagenauer-Tsapis, R. (2000) Ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag budding by ubiquitin ligase Nedd4. J. Virol. 74, 13943–13953 CrossRef Medline
36. Winberg, G., Matskova, L., Chen, F., Plant, P., Rotin, D., Gish, G., Ingram, R., Ernberg, I., and Pawson, T. (2000) Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol. Cell. Biol. 20, 8526–8535 CrossRef Medline
37. Zhi, X., and Chen, C. (2012) WWP1: a versatile ubiquitin E3 ligase in human immuno­deficiency virus type 1. J. Virol. 79, 9038–9045 CrossRef Medline
38. Yuan, B., Campbell, S., Bacharach, E., Rein, A., and Goff, S. P. (2000) Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses. J. Virol. 74, 7250–7260 CrossRef Medline
39. Parent, L. J., Bennett, R. P., Craven, R. C., Nelle, T. D., Krishna, N. K., Bowzard, J. B., Wilson, C. B., Puffer, B. A., Montelaro, R. C., and Wills, J. W. (1995) Positively independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J. Virol. 69, 5455–5460 CrossRef Medline
40. Garnier, L., Wills, J. W., Verderame, M. F., and Sudol, M. (1996) WW domain and retrovirus budding. Nature 381, 744–745 CrossRef Medline
41. Göttlinger, H. G., Dorfman, T., Sodroski, J. G., and Haseltine, W. A. (1991) Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. U.S.A. 88, 3195–3199 CrossRef Medline
42. Wills, J. W., Cameron, C. E., Wilson, C. B., Xiang, Y., Bennett, R. P., and Leis, J. (1994) An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J. Virol. 68, 6605–6618 CrossRef Medline
43. Harty, R. N., Brown, M. E., Wang, G., Huibregtse, J., and Hayes, F. P. (2000) A P PXY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc. Natl. Acad. Sci. U.S.A. 97, 13871–13876 CrossRef Medline
44. Harty, R. N., Brown, M. E., McGettigan, J. P., Wang, G., Jayakar, H. R., Huibregtse, J. M., Whitt, M. A., and Schnell, M. J. (2001) Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J. Virol. 75, 10623–10629 CrossRef Medline
45. Kikonyogo, A., Bouamr, F., Vana, M. L., Xiang, Y., Aiyar, A., Carter, C., and Leis, J. (2001) Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells. Proc. Natl. Acad. Sci. U.S.A. 98, 11199–11204 CrossRef Medline
46. Yasuda, J., Nakao, M., Kawaoka, Y., and Shida, H. (2003) Nedd4 regulates egress of Ebola virus-like particles from host cells. J. Virol. 77, 9987–9992 CrossRef Medline
47. Blot, V., Perugi, F., Gay, B., Prévost, M. C., Briant, L., Tangy, F., Abril, H., Staub, O., Dokhélar, M. C., and Pique, C. (2004) Nedd4-1-mediated ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag trafficking towards the multiseculcular body pathway prior to virus budding. J. Cell Sci. 117, 2357–2367 CrossRef Medline
60. Martin-Serrano, J., Perez-Caballero, D., and Bieniasz, P. D. (2004) Context-dependent effects of L domains and ubiquitination on viral budding. J. Virol. 78, 5554–5563 CrossRef Medline

61. Segura-Morales, C., Pescia, C., Chatellard-Causse, C., Sadoul, R., Bertrand, E., and Basyuk, E. (2005) Tsg101 and Alix interact with murine leukemia virus Gag and cooperate with Nedd4 ubiquitin ligases during budding. J. Biol. Chem. 280, 27004–27012 CrossRef Medline

62. Chung, H. Y., Morita, E., von Schwedler, U., Muller, B., Krassulisch, H. G., and Sundquist, W. I. (2008) NEDD4L overexpression rescues the release and infectivity of human immunodeficiency virus type 1 constructs lacking PTAP and YPXL late domains. J. Virol. 82, 4884–4897 CrossRef Medline

63. Okumura, A., Pitha, P. M., and Harty, R. N. (2008) ISG15 inhibits Ebola virus budding. J. Virol. 82, 4898–4907 CrossRef Medline

64. Weiss, E. R., Popova, E., Yamanaka, H., Kim, H. C., Huibregtse, J. M., and G öttlinger, H. G. (2009) The ESCRT pathway and HIV-1 budding. Retrovirology 6, e1001107 CrossRef Medline

65. Ott, D. E., Coren, L. V., Copeland, T. D., Kane, B. P., Johnson, D. G., Morham, S. G., and Sundquist, W. I. (2008) NEDD4L overexpression rescues the release and infectivity of human immunodeficiency virus type 1 constructs lacking PTAP and YPXL late domains. J. Virol. 82, 4898–4907 CrossRef Medline

66. Dorjbal, B., Derse, D., Lloyd, P., Soheilian, F., Nagashima, K., and Bouamr, F. (2013) Ubiquitin protease 15 (UBP15) is necessary for HIV-1 budding. J. Virol. 87, 11430–11439 CrossRef Medline

67. Gadiecker, G., Lloyd, P. A., Soheilian, F., Nagashima, K., and Derse, D. (2007) The role of WWP1-Gag interaction and Gag ubiquitination in assembly and release of human T-cell leukemia virus type 1. J. Virol. 81, 9769–9777 CrossRef Medline

68. Basler, C. F. (2017) Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol. 39, 551–561 CrossRef Medline

69. Strack, B., Calistri, A., Craig, S., Popova, E., and Gottlinger, H. G. (2003) The role of ITCH protein in human T-cell leukemia virus type 1 release. J. Biol. Chem. 278, 31092–31104 CrossRef Medline

70. Sette, P., Nagashima, K., Piper, R. C., and Bouamr, F. (2013) Ubiquitin conjugation to Gag is essential for ESCRT-mediated HIV-1 budding. Retrovirology 10, 79 CrossRef Medline

71. Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Co  ´te´, M., Rich, D. M. (2017) The pathogenesis of Ebola virus disease. Adv. Virol. 2017, 1–15 CrossRef Medline

72. Wirblich, C., Tan, G. S., Papaneri, A., Godlewski, P. J., Orenstein, J. M., and Harty, R. N. (2006) Filovirus assembly and budding. Methods Mol. Biol. 306, 61–70 CrossRef Medline

73. Harty, R. N. (2018) Hemorrhagic fever virus budding studies. Methods Mol. Biol. 1604, 209–215 CrossRef Medline

74. Harty, R. N., Paragas, J., Rasmussen, A. L. (2018) Host factors involved in Ebola virus replication. Curr. Top. Microbiol. Immunol. 419, 113–150 CrossRef Medline

75. Basler, C. F. (2017) Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol. 39, 551–561 CrossRef Medline

76. Basler, C. F. (2017) Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol. 39, 551–561 CrossRef Medline

77. Basler, C. F. (2017) Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol. 39, 551–561 CrossRef Medline
tein by use of rhabdovirus-retrovirus chimeras. J. Virol. 73, 3359–3365 CrossRef Medline

100. Jayakar, H. R., Murti, K. G., and Whitt, M. A. (2000) Mutations in the PPFY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release. J. Virol. 74, 9818–9827 CrossRef Medline

101. Jayakar, H. R., Jeetendra, E., and Whitt, M. A. (2004) Rhabdovirus assembly and budding. Virus Res. 106, 117–132 CrossRef Medline

102. Urata, S., Noda, T., Kawaoka, Y., Morikawa, S., Yokosawa, H., and Yasuda, J. (2007) Interaction of Tsg101 with Marburg virus VP40 depends on the PPFY motif, but not the PT/SAP motif as in the Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J. Virol. 81, 4895–4899 CrossRef Medline

103. Liang, J., Sagum, C. A., Bedford, M. T., Sidhu, S. S., Sudol, M., Han, Z., and Harty, R. N. (2017) Chaperone-mediated autophagy protein BAG3 negatively regulates Ebola and Marburg VP40-mediated egress. PLoS Pathog. 13, e1006132 CrossRef Medline

104. Behl, C. (2016) Breaking BAG: the co-chaperone BAG3 in health and disease. Trends Pharmacol. Sci. 37, 622–688 CrossRef Medline

105. Ulbricht, A., Gehlert, S., Leciejewski, B., Schiffer, T., Bloch, W., and Höhfeld, J. (2013) Tension-induced autophagy: may the pushed PPxY motif facilitate adenovirus entry. PLoS Pathog. 9, e1003585 CrossRef Medline

106. Ulbricht, A., and Höhfeld, J. (2013) Tension-induced autophagy: may the chaperone be with you. Autophagy 9, 920–922 CrossRef Medline

107. Pathak, B., Gehlert, S., Ulbricht, A., Ludecke, L., Tapia, V. E., Orfano, Z., Wenzel, D., Bloch, W., Volkmer, R., Fleischmann, B. K., Förster, D. O., and Höhfeld, J. (2017) The chaperone BAG3 coordinates protein synthesis and autophagy under mechanical strain through spatial regulation of mTORC1. Biochim. Biophys. Acta 1864, 62–75 CrossRef Medline

108. Ulbricht, A., Arndt, V., and Höhfeld, J. (2013) Chaperone-assisted proteostasis is essential for mechanotransduction in mammalian cells. Com. Integr. Biol. 6, e29925 CrossRef Medline

109. Sang, Y., Zhang, R., Scott, R. W., Creagh, A. L., Haynes, C. A., and Straus, S. K. (2017) U24 from Roseolovirus interacts strongly with Neddy4 WW domains. Sci. Rep. 7, 99776 CrossRef Medline

110. Sullivan, B. M., and Coscøy, L. (2008) Downregulation of the T-cell receptor complex and impairment of T-cell activation by human herpesvirus 6 U24 protein. J. Virol. 82, 602–608 CrossRef Medline

111. Sullivan, B. M., and Coscøy, L. (2010) The U24 protein from human herpesvirus 6 and 7 affects endocytic recycling. J. Virol. 84, 1265–1275 CrossRef Medline

112. Xiao, L. E., Johnson, L. J., and Yang, X. (2010) Interactions of U24 from Roseolovirus with WW domain-containing oxidoreductase is involved in upregulation of matrix metalloproteinase 9 by Epstein-Barr virus latent membrane protein 2A. Biochim. Biophys. Res. Commun. 436, 672–676 CrossRef Medline

113. Tejada-Simon, M. V., Zang, Y. C., Hong, J., Rivera, V. M., and Zhang, J. Z. (2003) Cross-reactivity with myelin basic protein and human herpesvirus 6 in multiple sclerosis. Ann. Neurol. 53, 189–197 CrossRef Medline

114. Wang, Y., Tung, W. R., Kwon, H. S., and Lee, J. (2003) Interactions of U24 from Roseolovirus with WW domains: canonical vs noncanonical. Biochem. Cell Biol. 81, 350–358 CrossRef Medline

115. Savioni, S., Alfaras-Andre, G., and Nagy, P. D. (2014) Tombusvirus-yeast interactions identify conserved cell-intrinsic viral restriction factors. Front. Plant Sci. 5, 383 CrossRef Medline

116. Qin, J. (2012) An inhibitory function of WW domain-containing host proteins in RNA virus replication. Virology 426, 106–119 CrossRef Medline

117. JBC REVIEWS: Viruses go modular

118. Barajas, D., Kövály, N., Qin, J., and Nagy, P. D. (2015) Novel mechanism of regulation of tomato bushy stunt virus replication by cellular WW-domain proteins. J. Virol. 89, 2061–2079 CrossRef Medline

119. Chesarino, N. M., McMichael, T. M., and Yount, J. S. (2015) E3 ubiquitin ligase NEDD4 promotes influenza virus infection by decreasing levels of the antiviral protein IFITM3. PLoS Pathog. 11, e1005095 CrossRef Medline
140. Okumura, A., Lu, G., Pitha-Rowe, I., and Pitha, P. M. (2006) Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 1440–1445 CrossRef Medline

141. Harty, R. N., Pitha, P. M., and Okumura, A. (2009) Antiviral activity of innate immune protein ISG15. *J. Innate Immun.* **1**, 397–404 CrossRef Medline

142. Malakhova, O. A., and Zhang, D. E. (2008) ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. *J. Biol. Chem.* **283**, 8783–8787 CrossRef Medline

143. Kuang, Z., Seo, E. J., and Leis, J. (2011) Mechanism of inhibition of retrovirus release from cells by interferon-induced gene ISG15. *J. Virol.* **85**, 7153–7161 CrossRef Medline

144. Pincetic, A., Kuang, Z., Seo, E. J., and Leis, J. (2010) The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. *J. Virol.* **84**, 4725–4736 CrossRef Medline

145. Seo, E. J., and Leis, J. (2012) Budding of enveloped viruses: interferon-induced ISG15-antivirus mechanisms targeting the release process. *Adv. Virol.* **2012**, 532723 CrossRef Medline

146. Morales, D. J., and Lenschow, D. J. (2013) The antiviral activities of ISG15. *J. Mol. Biol.* **425**, 4995–5008 CrossRef Medline

147. Villarroya-Beltri, C., Guerra, S., and Sánchez-Madrid, F. (2017) ISGylation - a key to lock the cell gates for preventing the spread of threats. *J. Cell Sci.* **130**, 2961–2969 CrossRef Medline

148. Han, Z., Lu, J., Liu, Y., Davis, B., Lee, M. S., Olson, M. A., Ruthel, G., Freedman, B. D., Schnell, M. J., Wrobel, J. E., Reitz, A. B., and Harty, R. N. (2014) Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. *J. Virol.* **88**, 7294–7306 CrossRef Medline

149. Sterling, T., and Irwin, J. J. (2015) ZINC 15–ligand discovery for every-one. *J. Chem. Inf. Model.* **55**, 2324–2337 CrossRef Medline

150. Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., and Coleman, R. G. (2012) ZINC: a free tool to discover chemistry for biology. *J. Chem. Inf. Model.* **52**, 1757–1768 CrossRef Medline

151. Loughran, H. M., Han, Z., Wrobel, J. E., Decker, S. E., Ruthel, G., Freedman, B. D., Harty, R. N., and Reitz, A. B. (2016) Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress. *Bioorg. Med. Chem. Lett.* **26**, 3429–3435 CrossRef Medline

152. Billioux, B. J. (2017) Neurological complications and sequelae of Ebola virus disease. *Curr. Infect. Dis. Rep.* **19**, 19 CrossRef Medline

153. Jacobs, M., Rodger, A., Bell, D. J., Bhagani, S., Cropley, I., Filipe, A., Gifford, R. J., Hopkins, S., Hughes, J., Jabeen, F., Johannessen, I., Karageorgopoulos, D., Lackenby, A., Lester, R., Liu, R. S., et al. (2016) Late Ebola virus relapse causing meningencephalitis: a case report. *Lancet* **388**, 498–503 CrossRef Medline

154. Steptoe, P. J., Scott, J. T., Sahr, F., Vandy, M., Harding, S. P., Beare, N. A. V., and Semple, M. G. (2018) Re: Shantha et al.: Ophthalmic manifestations and consequences of visual impairment in Ebola virus disease survivors in Monrovia, Liberia. *(Opthalmology. 2017;124:170–177).* *Ophthalmology* **125**, e19 CrossRef Medline

155. Shantha, J. G., Crozier, I., and Yeh, S. (2017) An update on ocular complications of Ebola virus disease. *Curr. Opin. Ophthalmol.* **28**, 600–606 CrossRef Medline

156. Hereith-Hebert, E., Bah, M. O., Etard, J. F., Sow, M. S., Resnikoff, S., Farreau, C., Toure, A., Ouenouden, A. N., Sagnon, I. C., March, L., Izard, S., Lama, P. L., Barry, M., Delaporte, E., and Postebogui Study Group (2017) Ocular complications in survivors of the Ebola outbreak in Guinea. *Am. J. Ophthalmol.* **175**, 114–121 CrossRef Medline

157. Shantha, J. G., Yeh, S., and Nguyen, Q. D. (2016) Ebola virus disease and the eye. *Curr. Opin. Ophthalmol.* **27**, 538–544 CrossRef Medline

158. Jampol, L. M., Ferris, F. L., 3rd, Bishop, D. J. (2015) Ebola and the eye. *JAMA Ophthalmol.* **133**, 1105–1106 CrossRef Medline

159. Moshifmar, F., Fenzl, C. R., and Li, Z. (2014) What we know about ocular manifestations of Ebola. *Clin. Ophthalmol.* **8**, 2355–2357 CrossRef Medline

160. Caswell, R. J., and Manavi, K. (2017) Emerging sexually transmitted viral infections: 1. Review of Ebola virus disease. *Int. J.STD AIDS* **28**, 1352–1359 CrossRef Medline

161. Sissoko, D., Keita, M., Diallo, B., Aliabadi, N., Fitter, D. L., Dahl, B. A., Akoi Bore, J., Raymond Koundouno, F., Singethan, K., Meisel, S., Enkirch, T., Mazzarelli, A., Amburgey, V., Faye, O., Alpha Sall, A., et al. (2017) Ebola virus persistence in breast milk after no reported illness: a likely source of virus transmission from mother to child. *Clin. Infect. Dis.* **64**, 513–516 Medline

162. Crozier, I. (2016) Ebola virus RNA in the semen of male survivors of Ebola virus disease: the uncertain gravitas of a privileged persistence. *J. Infect. Dis.* **214**, 1467–1469 CrossRef Medline

163. Uyeki, T. M., Erickson, B. R., Brown, S., McElroy, A. K., Cannon, D., Mehta, A. K., Lyon, G. M., 3rd, Varkey, J. B., Ribner, B. S., Ellison, R. T., 3rd, et al. (2016) Ebola virus persistence in semen of male survivors. *Clin. Infect. Dis.* **52**, 1502–1505 CrossRef Medline

164. Chughtai, A. A., Barnes, M., and Macintyre, C. R. (2016) Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. *Epidemiol. Infect.* **144**, 1652–1660 CrossRef Medline

165. Rogstad, K. E., and Tunbridge, A. (2015) Ebola virus as a sexually transmitted infection. *Curr. Opin. Infect. Dis.* **28**, 83–85 CrossRef Medline

166. Verdin, G. L., and Hillinski, G. J. (2012) Stapled peptides for intracellular drug targets. *Methods Enzymol.* **503**, 3–33 CrossRef Medline

167. Tan, B. X., Brown, C. J., Ferrer, F. J., Yuen, T. Y., Quah, S. T., Chan, B. H., Lam, P. K., Liu, M., Lam, Y. N., et al. (2015) Ebola virus persistence in semen of male survivors. *Epidemiol. Infect.* **143**, 1441–1451 CrossRef Medline

168. Zhang, H., Curreli, F., Zhang, X., Bhattacharya, S., Waheed, A. A., Coope, A., Couburn, D., Freed, E. O., and Debnath, A. K. (2011) Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain. *Retrovirology* **8**, 23 CrossRef Medline